Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for Anxiety in Youth with ASD
NCT03432065Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of buspirone in anxiety disorder, sponsored by Massachusetts General Hospital. Planned start Dec 2024; status: withdrawn.
02
Drugs
buspirone
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT03432065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432065.